AI in drug development

Digital

A close examination of the current and future role of AI in biomarker discovery and the challenges that developers face in leveraging it.

News

Ignota Labs of the UK has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US firm ceased operations earlier this year.

R&D

Hilary Eaton, a rare disease advocate and chief business officer at Profluent, discusses AI-first protein design and accelerating biomedicine.

R&D

Ben Sidders, chief scientific officer at Biorelate, discusses leveraging advanced data science methods to transform the focus and impact of R&D.

R&D

The first era of AI in pharma was built on potential. This next era will be built on proof, reinforcing even greater potential.

Digital

Web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about effectively implementing AI.